Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 7/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.42 |
| ▸ | GRM6 | O15303 | 4/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6065064 | 0.81 | GRIK1 (0.45) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3309307 | 0.77 | PTGS1 (0.41) | GRIK1PTGS1PTGS2 | |
| SCHEMBL4426861 | 0.77 | CTSK (0.47) | — | |
| Hydrochloric Acid SCHEMBL3306995 | 0.76 | PTGS1 (0.40) | GRIK1PTGS1PTGS2 | |
| SCHEMBL6378815 | 0.73 | GRIK1 (0.52) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL13397068 | 0.73 | SLC1A1 (0.40) | GRM8GRM4GRM6GRIK1GRIA1 | |
| SCHEMBL18886122 | 0.72 | GRIK1 (0.51) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3305810 | 0.72 | LMNA (0.44) | GRIK1PTGS1PTGS2LTA4H | |
| SCHEMBL3307185 | 0.72 | PTGS1 (0.46) | GRIK1PTGS1PTGS2 | |
| SCHEMBL456815 | 0.71 | NOS1 (0.45) | GRM8GRM4GRM6GRIK1GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635816-B1 | ENALAPRIL-NITROXYDERIVATIVES DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX SA (FR) | 2009-03-04 | — | — | EP | disclosed |
| US-7217733-B2 | ACE inhibitor derivatives | NICOX, S.A. (FR) | 2007-05-15 | — | — | US | disclosed |
| EP-1635816-A1 | ENALAPRIL-NITROXYDERIVATIVES DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Nicox S.A. (FR) | 2006-03-22 | — | — | EP | disclosed |
| US-20050004100-A1 | ACE inhibitor derivatives | NICOX S.A. (FR) | 2005-01-06 | — | — | US | disclosed |
| WO-2004110432-A1 | ENALAPRIL-NITROXYDERIVATIVES DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX S.A. (FR) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004100-A1 | ACE inhibitor derivatives | ACE, ACE2, AGTR1 | GRM8 3712/4885GRM4 3232/4885GRM6 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.